Prelude Therapeutics (PRLD) Other Non-Current Assets (2020 - 2026)
Prelude Therapeutics (PRLD) posted Other Non-Current Assets of $3.2 million for Q1 2026, up 2840.91% sequentially from $110000.0 in Q4 2025, and down 20.0% YoY from $4.0 million in Q1 2025.
Prelude Therapeutics (PRLD) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Prelude Therapeutics has reported Other Non-Current Assets for 7 years, with the latest figure at $3.2 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 20.0% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 20.0% YoY) and the FY2025 annual result came in at $110000.0, changed 0.0% from the prior year.
- Other Non-Current Assets climbed to $3.2 million in Q1 2026 per PRLD's latest filing, from $110000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $12.5 million in Q3 2023 and troughed at $110000.0 in Q4 2024.
- A 5-year average of $3.0 million and a median of $3.2 million in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets jumped 1674.26% in 2022, then sank 96.75% in 2024.
- Over 5 years, Other Non-Current Assets stood at $5.4 million in 2022, then slumped by 94.51% to $295000.0 in 2023, then tumbled by 62.71% to $110000.0 in 2024, then changed by 0.0% to $110000.0 in 2025, then soared by 2840.91% to $3.2 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $3.2 million, $110000.0, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 3.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.41 Mn |
| Mar 31, 2026 | 3.24 Mn |
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 110,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 405,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Sep 30, 2023 | 12.47 Mn |
| Jun 30, 2023 | 4.04 Mn |
| Mar 31, 2023 | 4.04 Mn |
| Dec 31, 2022 | 5.38 Mn |
| Sep 30, 2022 | 4.93 Mn |
| Jun 30, 2022 | 4.04 Mn |
| Mar 31, 2022 | 309,000.00 |
| Dec 31, 2021 | 303,000.00 |
| Dec 31, 2020 | 301,000.00 |